
Douglas Rissing
Recursion pharmaceuticals (RXRX) added ~11% on Wednesday morning after JP Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing blockbuster sales potential for the company’s lead asset, REC-4881.
Analyst Priyanka Grover argued that REC-4881, for which








